Patents Examined by Christine J. Saoud
  • Patent number: 11827715
    Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: November 28, 2023
    Assignee: OncoResponse, Inc.
    Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
  • Patent number: 11819541
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: November 21, 2023
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin, David W. Dodick
  • Patent number: 11820801
    Abstract: The present invention relates to a fusion protein comprising an extracellular domain of leucine-rich and immunoglobulin-like domains-1 (Lrig-1) protein and an immunoglobulin Fc region. The fusion protein provided in the present invention can interact with a ligand for Lrig-1 protein, which is present on effector T cells, to inhibit the interaction between the effector T cells and regulatory T cells (Treg cells) having the Lrig-1 protein on their surface, so that activity of the regulatory T cells is inhibited and activity of the effector T cells is maintained or elevated, thereby effectively inhibiting growth of cancer cells, in particular, solid cancer cells.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: November 21, 2023
    Assignee: Good T Cells, Inc.
    Inventors: Jung Ho Kim, Beom Seok Kim
  • Patent number: 11802151
    Abstract: The present disclosure provides an antibody that binds human Adhesion G Protein-Coupled Receptor B1 (BAI1) protein, compositions comprising the same, and use thereof in methods of detection, methods of diagnosis, and methods of treatment.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: October 31, 2023
    Assignee: Code Biotherapeutics, Inc.
    Inventors: Robert Getts, Jessica Bowers, Mindy Ellen George-Weinstein, Jacquelyn Gerhart
  • Patent number: 11787839
    Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: October 17, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventor: Hui-lin Pan
  • Patent number: 11786578
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: October 17, 2023
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Patent number: 11786585
    Abstract: Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) agonists and methods of their use to treat diseases involving IGFBP-3 and IGFBP-3R are provided. The agonists may be antibodies or other molecules specific for binding to and activating IGFBP-3R. The agonists are used to treat e.g. cancer, metabolic syndrome and obstructive respiratory disorders. In addition, methods of diagnosing cancer and predicting the chance of recurrence, metastasis and/or survival by measuring the level of IGFBP-3R in tumor tissue are provided.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: October 17, 2023
    Assignee: Virginia Commonwealth University
    Inventors: Youngman Oh, Qing Cai
  • Patent number: 11780914
    Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: October 10, 2023
    Inventors: Agnes E. Hamburger, Cen Xu, Hong Sun, Yuan D. Shih, Dohan Weeraratne
  • Patent number: 11780916
    Abstract: Provided herein are a gastric inhibitory polypeptide receptor (GIPR) antibody and its fusion protein with glucagon-like peptide-1 (GLP-1), and a pharmaceutical composition thereof. Also provided herein is a method for using the GIPR antibody and its fusion protein with GLP-1 to treat, prevent or improve one or more symptoms of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes or obesity.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: October 10, 2023
    Assignee: Gmax Biopharm LLC
    Inventors: Xiaofeng Wang, Hua Zhang, Chenjiang Yao, Cheng Zhang, Shuqian Jing
  • Patent number: 11771748
    Abstract: The present invention provides compositions and methods for treating tumor-induced osteomalacia. The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: October 3, 2023
    Assignees: Ultragenyx Pharmaceutical Inc., Kyowa Kirin Co., Ltd.
    Inventors: Emil D. Kakkis, Javier San Martin, Tomohiro Sudo
  • Patent number: 11760799
    Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: September 19, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Zhiqiang An, Ningyan Zhang, Philipp E. Scherer, Shangang Zhao
  • Patent number: 11753460
    Abstract: The present application relates to compositions comprising fusion proteins and cells expressing the proteins. The application further relates to methods of using the fusion proteins, cells, and compositions for modulating cell signaling and for selective expansion of cells.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: September 12, 2023
    Assignee: Seattle Children's Hospital
    Inventor: Andrew M. Scharenberg
  • Patent number: 11746134
    Abstract: The present disclosure relates to a human FGF21 mutant with improved effectiveness and stability, preparation method and pharmaceutical composition comprising the mutant, and a use thereof, and specifically relates to a human fibroblast growth factor 21 (FGF21) mutant, a gene encoding the same, and a method for preparing the mutant and a method of using the mutant for treating type 2 diabetes, obesity, dyslipidemia, or metabolic disorders.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 5, 2023
    Assignee: Heifei Zhongke Longwood Biotechnology Co., Ltd.
    Inventors: Junfeng Wang, Hongxin Zhao, Lei Zhu
  • Patent number: 11746140
    Abstract: Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ib? that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: September 5, 2023
    Assignee: F. HOFFMAN-LA ROCHE AG
    Inventors: Elizabeth Booth, Virginia Montanini, John A. Hall, Jody Berry
  • Patent number: 11738064
    Abstract: The present invention relates to a pharmaceutical composition comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide is fused to an anti-vascular endothelial growth factor agent, methods of treating eye diseases with the pharmaceutical composition, and a method for preparing an anti-VEGF agent with an improved efficacy and ability to overcome resistance.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: August 29, 2023
    Assignee: ILDONG PHARM CO., LTD.
    Inventors: Seong Beom Kim, Hyei Yoon Jung, Seok Woo Yang, Hyuk Sang Kwon, Jae-Hoon Kang, Yong-Sung Kim
  • Patent number: 11730762
    Abstract: The present disclosure relates to the field of biotechnology, and more specifically, to single-chain and multi-chain chimeric polypeptides having a linker domain positioned between two target-binding domains that are useful for a variety of applications including, without limitation, stimulating an immune cell, inducing or increasing proliferation of an immune cell, inducing differentiation of an immune cell, or treating a subject in need thereof (e.g., a subject having cancer or an aging-related disease or condition).
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: August 22, 2023
    Assignee: HCW Biologics, Inc.
    Inventor: Hing Wong
  • Patent number: 11730794
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: August 22, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: George Yancopoulos
  • Patent number: 11732024
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: August 22, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Patent number: 11725048
    Abstract: The present invention relates to C-X-C motif chemokine ligand 10 (CXCL10) binding proteins and uses thereof in methods of detecting and/or diagnosing a condition in a subject, comprising determining a level of CXCL10 in the subject. Specific antibodies that bind to total CXCL10 (full-length, N-terminally truncated and citrullinated) and antibodies that bind active CXCL10 (full-length) were used to measure the level of total and active CXCL10 in samples from ovarian cancer patients. The calculated ratio of active to total CXCL10 was lower in patients with malignant condition when compared to patients with benign tumours or healthy individuals and is the basis of method of diagnosis of malignant conditions, monitoring tumour burden and disease progression.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: August 15, 2023
    Inventors: Andrew N. Stephens, Adam Rainczuk, Sung-Woog Kang
  • Patent number: 11723982
    Abstract: The present disclosure provides methods of treating an ocular disease or disorder. The methods involve direct administration into the eye of a conjugate comprising a biologically active polypeptide and a biocompatible polymer.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: August 15, 2023
    Assignee: The Regents of the University of California
    Inventors: Kevin E. Healy, Eda Isil Altiok, David V. Schaffer, Wesley M. Jackson